{"id":32909,"date":"2014-10-07T10:54:37","date_gmt":"2014-10-07T14:54:37","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32909"},"modified":"2014-10-07T10:54:37","modified_gmt":"2014-10-07T14:54:37","slug":"foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909","title":{"rendered":"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/07\/2014 (wallstreetpr) \u2013 <strong>Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)<\/strong> disclosed that it has started Phase II study with FDX104, its contemporary formulation of doxycycline. This is to put a stop to the rash in cancer patients preferring epidermal growth factor receptor inhibitors of EGFRI.<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Acne-Like Rashes<\/strong><\/p>\n<p style=\"text-align: justify;\">According to a <a href=\"http:\/\/finance.yahoo.com\/news\/foamix-pharmaceuticals-ltd-announces-initiation-120000773.html\" target=\"_blank\">statement<\/a> issued to the media, patients of 45% and 100%, who are taking drugs for EGFRI like Vectribix and Erbitux, were affected by rigorous acne-like rashes.\u00a0Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) pointed out that the trial was the second stage multicenter, double-blind, randomized, vehicle-controlled clinical trial. This is meant to investigate the tolerability, safety and efficacy of FDX104 administered specifically for the prevention of EGFRI associated skin toxicity in 24 patients with cancer.<\/p>\n<p style=\"text-align: justify;\">Foamix indicated that there was a preliminary period of screening, i.e. five weeks of treatment. After this, a post-treatment would be followed up after four weeks.\u00a0Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) pointed out that it would take about seven days following the study drug initiation and randomization; patients would commence their EGFRI treatment.<\/p>\n<p style=\"text-align: justify;\">Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)\u00a0stated that the principal aim was to illustrate the tolerability and safety of FDX104 adjunct to any one of Vectibix or Erbitux treatment. It said that tolerability and safety would be investigated by measurements of key signs, severity of adverse events, incidence and skin tolerability evaluation. The company disclosed that the study was taking place in Israel.<\/p>\n<p style=\"text-align: justify;\"><strong>Management Comments<\/strong><\/p>\n<p style=\"text-align: justify;\">Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)\u00a0CEO, Dov Tamarkin, said that skin rash was the most commonly witnessed side effects in patients taking treatment with EGFRI. As a result, it had the possibility of patients changing their dosages of the drugs for anti-cancer or even discontinuing the treatment fully. He said that its FDX104 trial was meant to take care of such patients with topical foam of convenience. At the same time, it would avoid the risk of the systemic side effects apart from any possible drug-drug interactions of oral antibiotics.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/07\/2014 (wallstreetpr) \u2013 Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) disclosed that it has started Phase II study with FDX104, its contemporary formulation of doxycycline. This [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":32912,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[10194,10195,10196],"stock_ticker":[],"class_list":["post-32909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-dov-tamarkin","tag-foamix-pharmaceuticals-ltd-nasdaqfomx","tag-nasdaqfomx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/07\/2014 (wallstreetpr) \u2013 Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) disclosed that it has started Phase II study with FDX104, its contemporary formulation of doxycycline. This [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-07T14:54:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"160\" \/>\n\t<meta property=\"og:image:height\" content=\"68\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash\",\"datePublished\":\"2014-10-07T14:54:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg\",\"keywords\":[\"Dov Tamarkin\",\"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)\",\"NASDAQ:FOMX\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909\",\"name\":\"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg\",\"datePublished\":\"2014-10-07T14:54:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg\",\"width\":160,\"height\":68},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909","og_locale":"en_US","og_type":"article","og_title":"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash - Wall Street PR","og_description":"Boston, MA 10\/07\/2014 (wallstreetpr) \u2013 Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) disclosed that it has started Phase II study with FDX104, its contemporary formulation of doxycycline. This [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-07T14:54:37+00:00","og_image":[{"width":160,"height":68,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash","datePublished":"2014-10-07T14:54:37+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg","keywords":["Dov Tamarkin","Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)","NASDAQ:FOMX"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909","url":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909","name":"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg","datePublished":"2014-10-07T14:54:37+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/images.jpg","width":160,"height":68},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/foamix-pharmaceuticals-ltd-nasdaqfomx-starts-phase-ii-trial-with-fdx104-in-chemotherapy-induced-rash-32909#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Starts Phase II Trial With FDX104 In Chemotherapy Induced Rash"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32909"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/32912"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32909"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}